Business Context and Reporting Period
This Form 8-K was filed by AgeX Therapeutics, Inc. (trading symbol: AGE) on February 14, 2022. The filing reports the entry into a material definitive agreement with Juvenescence Limited to secure a line of credit intended to refinance existing debt and fund operations. The company is an emerging growth company incorporated in Delaware.
Key Financial Metrics and Transaction Details
- Line of Credit: A $13,160,000 secured convertible promissory note was established with a 12-month draw period.
- Initial Draw: AgeX drew $8,160,000 immediately upon execution.
- Use of Proceeds: $7,160,000 was used to repay the outstanding principal and fees of a 2019 Loan Facility with Juvenescence; the remainder is available for working capital and R&D.
- Remaining Availability: $5,000,000 remains available for future draws, subject to lender discretion and a $1,000,000 cap per single draw.
- Cost of Capital: In lieu of interest, an Origination Fee of 4% applies to each draw, plus an additional 4% on total funds drawn after the 12-month draw period.
- Warrants Issued: 5,230,768 warrants were issued for the initial draw at an exercise price of $0.78 per share (50% of the draw amount divided by market price).
- Repayment Date: February 14, 2024.
Material Changes and Conversion Terms
The transaction represents a refinancing of prior debt with new terms allowing for potential equity conversion. The note includes two conversion mechanisms:
- Borrower Conversion: AgeX may convert the loan balance into common stock if it consummates a "Qualified Offering" (gross proceeds of at least $10 million). The conversion price would be the lowest price in that offering.
- Lender Conversion: Juvenescence may convert the outstanding amount into common stock at any time at the closing market price on the day prior to notice.
- Blocker Provisions: Conversions are restricted to prevent violating NYSE American rules regarding the issuance of 20% or more of outstanding stock at a discount (the "20% Rule") or causing a change of control (50% ownership). AgeX has agreed to seek stockholder approval to override these blockers if necessary.
Restrictive Covenants and Collateral
AgeX granted Juvenescence a security interest in substantially all of its assets. Covenants restrict the incurrence of additional indebtedness (with specific exceptions for its subsidiary Reverse Bioengineering, Inc.) and mandate that proceeds be used for R&D, professional expenses, working capital, or debt repayment. Additional investments in subsidiaries require lender consent.
Outlook, Risks, and Contingencies
- Default Risks: The note contains extensive default provisions, including failure to pay, breach of covenants, insolvency, or material adverse changes in financial condition. Default triggers immediate repayment of the outstanding amount.
- Dilution Risk: The conversion features and warrant issuance create potential dilution for existing shareholders, subject to the 19.9% and 50% ownership blockers.
- Forward-Looking Statements: The filing includes standard disclaimers that actual results may differ from anticipated results due to various risk factors.
Investor Verification Checklist
- Verify the current outstanding balance of the Secured Note and any subsequent draws made after the initial $8.16 million.
- Confirm whether AgeX has consummated a "Qualified Offering" to trigger Borrower Conversion rights.
- Review the latest stock price to assess the potential dilution impact if Juvenescence exercises the 5,230,768 warrants at $0.78 per share.
- Check for any stockholder votes regarding the override of the 19.9% or 50% conversion blockers.
- Monitor compliance with the restrictive covenants, particularly regarding the subsidiary Reverse Bioengineering, Inc. and the prohibition on additional indebtedness.